Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Current Assets Current Deferred Revenue Current Taxes Finished Goods Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Sarepta Therapeutics (SRPT) Current Leases (2022 - 2023)

Sarepta Therapeutics has reported Current Leases over the past 2 years, most recently at $17.8 million for Q4 2023.

For Q4 2023, Current Leases rose 15.21% year-over-year to $17.8 million; the TTM value through Dec 2023 reached $17.8 million, up 15.21%, while the annual FY2023 figure was $17.8 million, 15.21% up from the prior year.
Current Leases for Q4 2023 was $17.8 million at Sarepta Therapeutics, up from $15.5 million in the prior quarter.
Over five years, Current Leases peaked at $17.8 million in Q4 2023 and troughed at $15.5 million in Q4 2022.